Through possible limited availability of intravenous immunoglobulins, there is a threat of a shortage in some hospitals in Belgium. The Federal Agency for Medicines and Health Products (FAMHP) is giving recommendations for hospital pharmacists and physician-specialists within the hospitals.
There are 2 result(s) found based on your search criteria
1-2 from 2 result(s)
Limited availability of intravenous immunoglobulins: recommendations to the attention of hospital pharmacists and the physician-specialists within hospitals where there is an availability problem.
Marevan (warfarin) from the manufacturer Therabel remains available on the Belgian market
After successful consideration among the FAMHP, the National Institute for Health and Disability Insurance (RIZIV-INAMI) and the manufacturer Therabel, the manufacturer has decided to continue to produce the drug Marevan. The FAMHP calls on pharmacists and patients to not order unnecessary inventories of the drug so that the drug will remain available for all patients.